Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call

 Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial
                         Results And Conference Call

PR Newswire

SAN DIEGO, Feb. 20, 2013

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative diagnostic testing and genetic analysis
solutions, today announced it will report financial results for the fourth
quarter and full year of 2012 after closing of the NASDAQ Global Market on
Thursday, March 7, 2013.

A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and
other members of senior management will take place on the same day at 5:00 pm
ET (2:00 pm PT) and will be webcast live on the Sequenom website.

To access the live teleconference call, dial 800-860-2442 in the U.S.,
866-605-3852 in Canada (both are toll free), and 412-858-4600 for other
international callers. Please specify to the operator that you would like to
join the "Sequenom Fourth Quarter 2012 Earnings Conference Call." If you are
unable to listen to the live webcast, a teleconference replay will be
available through Friday, March 15, 2013. Interested parties can access the
replay by dialing 877-344-7529 or 412-317-0088 internationally and entering
the conference number 10025204.

The conference call webcast is accessible through the "Investors" section of
the Sequenom website at An online replay will be
available following the initial broadcast until Friday, March 15, 2013.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular Medicine

Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited
and CLIA-certified molecular diagnostics laboratory with two locations
dedicated to the development and commercialization of laboratory developed
tests for prenatal and eye conditions and diseases. Utilizing innovative
proprietary technologies, Sequenom CMM provides test results that can be used
as tools by clinicians in managing patient care.Testing services are
available only upon request to physicians.Sequenom CMM works closely with key
opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom
CMM scientists use a variety of sophisticated and cutting-edge methodologies
in the development and validation of tests.Sequenom CMM is changing the
landscape in genetic diagnostics. Visit for more
information on laboratory testing services.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,; Jakob Jakobsen, Media
Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.